U.S. Environmental Protection Agency Human Studies Facility
Chapel Hill, North Carolina, 27514, United States
NCT Number: NCT03395119
Purpose: A growing body of epidemiological data suggests an increased risk of cardiovascular events associated with air pollution. One of the common air pollutants, ozone, has been shown to induce oxidative stress and inflammation in the cardiovascular and respiratory systems. This proposed study is to examine the efficacy of fish oil and olive oil in modulating cardiovascular and pulmonary functions after ozone exposure. The objective is to understand the mechanistic basis for the health effects of ozone relative to those air pollutants. Treatment groups will include forty healthy young adults who will be given dietary supplementation of fish oil or olive oil. A control group will consist of 20 healthy volunteers who will receive no supplements. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day. Cardiac rhythm, pulmonary function, vascular responses, endothelial function, and markers of coagulation and airway inflammation pre- and post- ozone exposure will be measured. This study is designed to build on the previous nutritional supplement interventional studies (UNC IRB # 07-0190 and UNC IRB # 11-1807), in order to understand the mechanism of action of particulate pollutants in comparison to that of ozone, a known oxidant air contaminant.
Participants: A total of sixty healthy 18-35 year-old male and female subjects will be involved in the study.
Procedures (methods): Forty healthy young adults will receive dietary supplementation consisting of fish oil or olive oil for 4 weeks. The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks of supplementation or control regiment, each subject will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day.
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Phase 1
Chapel Hill, North Carolina, 27514, United States
Ozone pollution is a common problem across the world, including in the US. This proposed study is to examine the efficacy of fish oil and olive oil in modulating cardiovascular and pulmonary functions after ozone exposure. Results from this study will also increase our understanding of how ozone exposure adversely affects the functioning of the human cardiovascular and respiratory systems. This understanding may be especially important for patients with cardiopulmonary diseases.
Approximately 60 people will participate in this study.
You should expect to be in this study for about a month, but your participation could possibly last for 6 months. There are 4 sessions, including a consenting session (today) which will last for about 4 hours. The two exposure-day sessions will last approximately 8-9 hours each. There will also be an approximately 3-hour follow-up visit the day after your last exposure.
What will happen if you take part in the study? Before you agree to participate in this study, you must read the consent forms in their entirety. The research and medical staff will then answer all your questions and explain all the risks involved in this study to your satisfaction.
You should have already undergone a general physical examination to ensure that you are a suitable candidate for this study. If you are a female, you will be asked about your menstrual history. For all other female participants, a pregnancy test will be performed today, and this will be repeated on the exposure day if more than 7 days since last pregnancy test.
Consenting Day We will go over the study in detail so that you will know what we will expect from you as a participant and what you should expect from us as investigators. If you agree to participate in the study, you will sign all study consent forms and receive one set of signed copies.
You will have a breathing test (spirometry). You will breathe through a filter into a plastic device. Your lung function test results should meet certain criteria (Both Forced Vital Capacity (FVC) and Forced Expiatory Volume at the 1st second (FEV1) are equal to and greater than 80% of the reference value) to allow you to participate in the study.
You will undergo a procedure for for induced sputum. If you are a non-producer or the quality of the induced sputum sample that you produce does not meet the study criteria (we will know the sputum quality in the next two days), we will exclude you from the study. If that happens, you will be reimbursed for the time and procedures for the consenting session. If you qualify, you will be given instructions to prepare for the exposure sessions. Then you will be scheduled for the exposure sessions.
You will be give dietary supplementation of fish oil, olive oil or placebo for 4 weeks. Dietary and medication instructions will be given to restrict certain types of food and medicines during the supplementation period.
Exposure days We will call you a few days before the exposure session to remind you of your scheduled visit. You should avoid smoke, fumes, alcohol, and strenuous exercise 24 hours prior to all visits, and abstain from pan fried or grilled meat after midnight of the exposure day.
You will be asked to eat a light breakfast and arrive at the EPA medical station by 7:30 am. Please understand that it is very important that you arrive by this time in order for the study team to process all of the samples and data. Please note that we may have to cancel your participation if you arrive late.
Prior to exposure, you will:
During the exposure, you will:
Immediately following the exposure, you will repeat the pre-exposure procedures and have a low fat lunch brought by you.
Follow up visit (about 3 hours) You will return to the HSF the next morning (approximately 18 hours after your 2nd exposure) and you will repeat the pre-exposure procedures.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Temporary exclusion criteria:
Use of other medications will be evaluated on a case-by-case basis. There is the potential that an individuals current medication use will preclude them from participating in the study at the current time, but they may be reassessed and potentially rescheduled for participation at a later time.
After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
Other names: Filtered air
3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver >60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
Other names: omega-3 fatty acids (eicosapentaenoic/docosahexaenoic)
3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
Other names: extra virgin olive oil
Time frame: Day 1, Day 2
FEV1 is determined by spirometry
Time frame: 1 hour pre-exposure, 1 hour post-exposure
Brachial artery ultrasound will be used to evaluate flow-mediated dilatation which will be performed in the Human Studies Facility (HSF) at U.S. Environmental Protection Agency (EPA) using an ultrasound instrument. The diameter of the brachial artery will be measured at baseline and during reactive hyperemia.
Time frame: 1 hour pre-exposure, 18 hour post-exposure
Brachial artery ultrasound will be used to evaluate flow-mediated dilatation which will be performed in the HSF at EPA using an ultrasound instrument. The diameter of the brachial artery will be measured at baseline and during reactive hyperemia.
Time frame: 30 min pre-exposure, 1 hour post-exposure
Retinal images will be taken using an FDA-approved, commercially available, non-mydriatic fundus camera. Images will be taken from both eyes.
Time frame: 30 min pre-exposure, 18 hour post-exposure
Retinal images will be taken using an FDA-approved, commercially available, non-mydriatic fundus camera. Images will be taken from both eyes.
Time frame: 6 weeks prior to the exposure, 4 hour post-exposure
Sputum induction will be performed to determine the airway inflammation.
Time frame: 1 hour pre-exposure, 1 hour post-exposure
Heart rate variability will be collected by the Holter monitor.
Time frame: 1 hour pre-exposure, 18 hour post-exposure
Heart rate variability will be collected by the Holter monitor.
Time frame: 6 weeks prior to the exposure, 2 hours pre-exposure
Blood sample will be collected for fatty acids analysis
Time frame: 2 hour pre-exposure, 30 min post-exposure
Blood sample will be collected for fatty acids analysis
Time frame: 2-hour pre-exposure, 18 hour post-exposure
Blood sample will be collected for fatty acids analysis
Time frame: 6 weeks prior to the exposure, 2 hours pre-exposure
Blood sample will be collected for measuring the cholesterol level
Time frame: 2 hour pre-exposure, 30 min post-exposure
Blood sample will be collected for measuring the cholesterol level
Time frame: 2-hour pre-exposure, 18 hour post-exposure
Blood sample will be collected for measuring the cholesterol level
Time frame: immediate post-exposure to ozone within 30 min, 18 hour post-exposure
Forced expired volume in the first second (FEV1) is determined by the spirometry
University of North Carolina, Chapel Hill
Other
Acronym: OMEGOZ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05738746
Dietary Supplement, Healthy
Szczecin, West Pomeranian Voivodeship, Poland
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial Details